Long-Term Data from Omidubicel Ph 3 Trial Demonstrates OS and Sustainable Durable Outcomes for Patients with Blood Cancers October 5, 2022
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance ADG106 in Combination with KEYTRUDA August 20, 2021
